|
|
Vaccine Detail
|
MVA-PSA/PAP Prostate Cancer Vaccine |
| Vaccine Information |
- Vaccine Name: MVA-PSA/PAP Prostate Cancer Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007544
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- KLK3
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- ACP3
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding genes for prostate specific antigen (PSA) and prostate acid phosphatase (PAP) with potential immunostimulatory and antineoplastic activities. Upon administration, MVA-PSA-PAP prostate cancer vaccine expresses PSA and PAP peptides, which may elicit humoral and cellular immune responses against prostate cancer cells expressing PSA and PAP. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. (NCIT_C74064).
|
| Host Response |
|
|
| References |
NCIT_C74064: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74064]
|
|
